Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
19
VOR Quote, Financials, Valuation and Earnings
Last price:
$11.68
Seasonality move
:
-27.45%
Day range:
$10.45 - $12.40
52-week range:
$2.62 - $65.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.13x
Volume:
1.6M
Avg. volume:
2.6M
1-year change:
-59.92%
Market cap:
$72.4M
Revenue:
--
EPS (TTM):
-$381.91
Analysts' Opinion
-
Consensus RatingVor Biopharma, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $43.25, Vor Biopharma, Inc. has an estimated upside of 308.79% from its current price of $10.58.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $32.00 representing 100% downside risk from its current price of $10.58.
Fair Value
-
According to the consensus of 6 analysts, Vor Biopharma, Inc. has 308.79% upside to fair value with a price target of $43.25 per share.
VOR vs. S&P 500
-
Over the past 5 trading days, Vor Biopharma, Inc. has underperformed the S&P 500 by -28.71% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Vor Biopharma, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vor Biopharma, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Vor Biopharma, Inc. reported revenues of --.
Earnings Growth
-
Vor Biopharma, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Vor Biopharma, Inc. reported earnings per share of -$121.63.
Enterprise value:
-95M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
0.66x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$3.8M
Return On Assets:
-1611.7%
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$9.2M | -$3.6M | -$3.8M | -$900K | -$2K | |
| Operating Income | -$122.6M | -$118M | -$367M | -$28.5M | -$28.1M | |
| EBITDA | -$113.5M | -$114.4M | -$363.2M | -$27.6M | -$28.1M | |
| Diluted EPS | -$1.88 | -$1.65 | -$381.91 | -$0.40 | -$121.63 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $232.1M | $142.7M | $164.4M | $67.3M | $172.5M | |
| Total Assets | $258.6M | $206.4M | $223M | $116M | $176.2M | |
| Current Liabilities | $9.2M | $11.1M | $15.4M | $14.3M | $18.8M | |
| Total Liabilities | $25.7M | $47.6M | $48.2M | $43M | $2.4B | |
| Total Equity | $233M | $158.7M | $174.8M | $73M | -$2.2B | |
| Total Debt | $16.5M | $36.5M | $32.9M | $28.7M | $2.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$94.6M | -$99.6M | -$144M | -$23.3M | -$53.7M | |
| Cash From Investing | -$36.4M | $107.3M | $100K | -$34K | -$244K | |
| Cash From Financing | $115.2M | $131K | $249.3M | $41K | $21.5M | |
| Free Cash Flow | -$95.9M | -$99.9M | -$144.7M | -$23.3M | -$53.9M | |
VOR
Sector
Market Cap
$72.4M
$28.1M
Price % of 52-Week High
16.08%
50.9%
Dividend Yield
0%
0%
Shareholder Yield
-72.99%
-1.55%
1-Year Price Total Return
-59.92%
-19.36%
Beta (5-Year)
--
0.498
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$13.04
200-day SMA
Sell
Level
$22.33
Bollinger Bands (100)
Sell
Level
12.57 - 37.41
Chaikin Money Flow
Sell
Level
-24.6M
20-day SMA
Sell
Level
$12.45
Relative Strength Index (RSI14)
Sell
Level
40.91
ADX Line
Sell
Level
25.36
Williams %R
Buy
Level
-97.9528
50-day SMA
Sell
Level
$13.99
MACD (12, 26)
Sell
Level
-0.27
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
65.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.7091)
Sell
CA Score
(Annual)
Level (-2.6425)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (5.1326)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, VOR has received 4 Buy ratings 2 Hold ratings, and 0 Sell ratings. The VOR average analyst price target in the past 3 months is $43.25.
-
Where Will Vor Biopharma, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vor Biopharma, Inc. share price will rise to $43.25 per share over the next 12 months.
-
What Do Analysts Say About Vor Biopharma, Inc.?
Analysts are divided on their view about Vor Biopharma, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vor Biopharma, Inc. is a Sell and believe this share price will drop from its current level to $32.00.
-
What Is Vor Biopharma, Inc.'s Price Target?
The price target for Vor Biopharma, Inc. over the next 1-year time period is forecast to be $43.25 according to 6 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is VOR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vor Biopharma, Inc. is a Buy. 4 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VOR?
You can purchase shares of Vor Biopharma, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vor Biopharma, Inc. shares.
-
What Is The Vor Biopharma, Inc. Share Price Today?
Vor Biopharma, Inc. was last trading at $11.68 per share. This represents the most recent stock quote for Vor Biopharma, Inc.. Yesterday, Vor Biopharma, Inc. closed at $10.58 per share.
-
How To Buy Vor Biopharma, Inc. Stock Online?
In order to purchase Vor Biopharma, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get VOR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
VOR
Sector
P/E ratio
--
24.09x
PEG ratio
0.00x
-0.01x
P/B ratio
3.13x
1.83x
Price / LTM sales
--
1.59x
Growth Metrics
VOR
Sector
Revenue growth
--
4.68%
Earnings growth
-30117.79%
10.88%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.97
-$0.18
Profitability
VOR
Sector
Profitability FY 2024
-$3.5M
$3.6M
Return on invested capital
--
-31.87%
Return on assets
-1611.7%
-28.18%
Return on equity
--
-37.89%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Feb
12
Balance Sheet
VOR
Sector
Total cash
$170.5M
$26.2M
Short term investments
$10M
$25.7M
Total assets
$153M
$76.7M
Long term debt
$2.8M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
RGC alert for Jan 6
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Buy
73
INOD alert for Jan 6
Innodata, Inc. [INOD] is up 4.84% over the past day.
Buy
65
AVAV alert for Jan 6
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
